迈威生物-U
(688062)
| 流通市值：40.55亿 | | | 总市值：79.36亿 |
| 流通股本：2.04亿 | | | 总股本：4.00亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,119,746,885.57 | 1,192,626,723.55 | 1,564,341,685.47 | 1,695,370,087.4 |
| 应收票据及应收账款 | 40,830,507.31 | 38,343,632.47 | 28,413,405.38 | 47,100,918.85 |
| 应收账款 | 40,830,507.31 | 38,343,632.47 | 28,413,405.38 | 47,100,918.85 |
| 预付款项 | 67,297,643.03 | 72,416,801.57 | 84,167,759.53 | 35,091,612.44 |
| 其他应收款合计 | 119,490,603.24 | 100,045,600.23 | 41,618,202.64 | 41,380,276.35 |
| 存货 | 220,223,362.99 | 211,682,026.16 | 208,969,757.94 | 173,244,661.06 |
| 其他流动资产 | 80,860,527.91 | 86,293,283.11 | 68,668,120.94 | 82,271,228.91 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,658,452,655.05 | 1,705,180,931.68 | 2,017,126,099.03 | 2,098,846,512.71 |
| 非流动资产: | | | | |
| 长期股权投资 | 57,800,098.18 | 46,657,884.43 | 44,631,578.72 | 40,647,856.53 |
| 其他非流动金融资产 | 695,836.24 | - | - | - |
| 固定资产 | 1,609,618,867.13 | 1,653,426,800.48 | 777,421,106.64 | 798,280,341.26 |
| 在建工程 | 260,159,857.13 | 240,871,410.78 | 1,009,848,245.24 | 993,981,820.91 |
| 使用权资产 | 150,435,200.52 | 158,649,552.92 | 166,747,855.56 | 174,714,499.67 |
| 无形资产 | 150,880,429.62 | 152,809,274.5 | 142,422,801 | 130,315,284.45 |
| 商誉 | 118,769,811.89 | 118,769,811.89 | 118,769,811.89 | 118,769,811.89 |
| 长期待摊费用 | 6,070,425.64 | 6,385,848.13 | 4,510,822.24 | 5,094,287.82 |
| 其他非流动资产 | 178,473,234.13 | 192,757,338.24 | 216,110,436.82 | 200,731,886.85 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,532,903,760.48 | 2,570,327,921.37 | 2,480,462,658.11 | 2,462,535,789.38 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 4,191,356,415.53 | 4,275,508,853.05 | 4,497,588,757.14 | 4,561,382,302.09 |
| 流动负债: | | | | |
| 短期借款 | 1,073,088,580 | 921,601,377.7 | 907,717,127.46 | 771,675,179.24 |
| 交易性金融负债 | - | - | 3,375,069.1 | 3,375,069.1 |
| 衍生金融负债 | 3,097,224.9 | 3,097,224.9 | - | - |
| 应付票据及应付账款 | 116,800,994.82 | 100,234,370.7 | 88,129,984.91 | 54,498,657.56 |
| 应付账款 | 116,800,994.82 | 100,234,370.7 | 88,129,984.91 | 54,498,657.56 |
| 合同负债 | 42,840,050.91 | 36,010,201.63 | 47,892,292.91 | 21,279,858.1 |
| 应付职工薪酬 | 84,836,561.47 | 74,786,921.48 | 56,220,985 | 51,294,813.43 |
| 应交税费 | 33,707,220.98 | 39,296,744.71 | 24,596,560.7 | 30,550,578.42 |
| 其他应付款合计 | 189,938,469.23 | 220,293,165.28 | 170,160,874 | 195,746,902.66 |
| 一年内到期的非流动负债 | 210,549,048.98 | 145,168,419.34 | 141,427,713.78 | 49,767,691.44 |
| 其他流动负债 | 1,549,678.25 | 1,227,230.44 | 3,565,047.03 | 582,163.92 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,756,407,829.54 | 1,541,715,656.18 | 1,443,085,654.89 | 1,178,770,913.87 |
| 非流动负债: | | | | |
| 长期借款 | 962,268,796.85 | 1,006,446,352.48 | 985,798,859.16 | 1,052,741,377.53 |
| 租赁负债 | 131,730,504.88 | 142,965,795.63 | 147,169,044.74 | 159,036,369.94 |
| 长期应付款 | 51,204,104.17 | - | - | - |
| 预计负债 | 1,569,301.9 | 1,529,301.9 | 924,334.32 | 769,944.02 |
| 递延收益 | 24,853,072.83 | 27,073,698.53 | 15,639,854.78 | 13,823,000 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 1,171,625,780.63 | 1,178,015,148.54 | 1,149,532,093 | 1,226,370,691.49 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 2,928,033,610.17 | 2,719,730,804.72 | 2,592,617,747.89 | 2,405,141,605.36 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 399,600,000 | 399,600,000 | 399,600,000 | 399,600,000 |
| 资本公积 | 5,959,508,386.5 | 5,959,464,861.03 | 5,959,402,817.93 | 5,959,318,670 |
| 其他综合收益 | 5,040,049.13 | 5,081,177.2 | 3,786,640.68 | 5,370,336.91 |
| 未分配利润 | -5,086,996,809.24 | -4,795,268,673.96 | -4,445,439,800.1 | -4,196,331,698.81 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,277,151,626.39 | 1,568,877,364.27 | 1,917,349,658.51 | 2,167,957,308.1 |
| 少数股东权益 | -13,828,821.03 | -13,099,315.94 | -12,378,649.26 | -11,716,611.37 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,263,322,805.36 | 1,555,778,048.33 | 1,904,971,009.25 | 2,156,240,696.73 |
| 负债和股东权益合计 | 4,191,356,415.53 | 4,275,508,853.05 | 4,497,588,757.14 | 4,561,382,302.09 |
| 公告日期 | 2025-04-29 | 2025-03-31 | 2024-10-31 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |